Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Paola Lucia Arrieta Narvaez (Madrid, Spain), Paola Lucía Arrieta Narváez, Esteban Pérez Rodríguez, Rosa Mariela Mirambeaux Villalona, Deisy Diana Barrios Barreto, Patricia Castro Acosta, Eva Mañas Baena. Predictive parameters of survival in malignant pleural effusion. Eur Respir J 2015; 46: Suppl. 59, 4353

Member's Comments

No comment yet.

Related content which might interest you: Lent score validation on patients with malignant pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 What outcome after pleurodesis in malignant pleural effusion in lung cancer? Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Role of Dr-70 immunoassay in suspected malignant pleural effusion Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Malignant pleural effusion (MPE) as debut of cancer Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Survival of non small cell lung carcinoma patients with malignant pleural effusions Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Blood-staining of pleural fluid is an inaccurate predictor of pleural malignancy Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Talc pleurodesis for malignant pleural effusion - effect on survival: Case-control follow-up study Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Ideal volume sampling in the diagnosis of malignant pleural effusions. Just how much is really enough? Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Malignant pleural effusion as the initial manifestation of gynecological malignancies Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 CT scanner for the pleural staging of pleural cancer: How accurate is this? Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Risk of occult pleural infection in patients with malignant effusions Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Pleural ultrasonic elastography in the diagnosis of malignant pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 An examination of the factors for successful pleurodesis against malignant pleural effusion (MPE) Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 LATE-BREAKING ABSTRACT: A proteomic study of benign and malignant pleural effusions Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Solitary fibrous tumour of the pleural: Two malignant cases Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016